MedTrace Logo

Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment

NCT04706598 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2024-07-12

No results posted yet for this study

Summary

This study will evaluate the safety and efficacy of bladder intravesical Camrelizumab in patients with high-risk non-muscle-invasive bladder cancer who failed BCG therapy.

Conditions

  • Urinary Bladder Neoplasms
  • Immunotherapy

Interventions

DRUG

Camrelizumab

Solution for Infusion (Intravesical)

Sponsors & Collaborators

  • Shanghai Shen Kang Hospital Development Center

    collaborator OTHER

  • Fudan University

    lead OTHER

Principal Investigators

  • Xiang Wang, MD · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

  • Yushan Liu, MD · Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine

  • Xudong Yao, MD · Shanghai Tenth People's Hospital,Shanghai Tong Ji University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-09
Primary Completion
2024-07-11
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04706598 on ClinicalTrials.gov